the Tumor Immunotherapy Discovery Engine

This project, based at the Broad Institute, aims to expand the screening universe of in vivo models, genes, and immunotherapies to enable discovery of novel mechanisms of resistance and enhanced sensitivity to cancer immunotherapy. We believe this is a powerful approach to identify synergistic targets and biomarkers to help patients.